Prelude Therapeutics Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly For Supply Of Its CDK4/6 Kinase Inhibitor, Abemaciclib And Its Oral Estrogen Receptor Antagonist Imlunestrant
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet